- Malaria Vaccine Initiative/ Program for Appropriate Technology in Health
- Bill and Melinda Gates Foundation
- Institut Pasteur (Michael White)
- Queen Mary's University (Jamie Griffin)
- London School of Hygiene and Tropical Medicine (Eleanor Riley & Chris Drakeley)
- GSK (Christophe Sauboin)
- Swiss Tropical and Public Health Institute (Melissa Penny, Katya Galactionova, Peter Pemberton-Ross & Tom Smith)
- Institute of Disease Modelling (Edward Wenger, Philip Eckhoff & Caitlin Bever)
- Wellcome-KEMRI Kilifi/University of Oxford (Philip Bejon & Ally Olutu)
In early 2014 the RTS,S malaria vaccine completed Phase III trials in 11 trial sites throughout sub-Saharan Africa. Throughout this period, and continuing into the future, we have been involved in modelling work to better understand the mode of action of the vaccine and to use these insights to estimate the cost-effectiveness and public health impact of the vaccine.
Starting with pooled data from the Phase II studies we developed models to identify the relationship between anti-CSP antibodies and protection against infection, and to estimate how immunity against infection and clinical disease wanes over time in different transmission settings. Upon completion of the Phase III trial we refitted this model with the more informative individual-level data, and used the fitted model to estimate the number of cases and deaths averted if the vaccine were to be rolled out under a variety of delivery regimens. Throughout this process we worked closely with the WHO and three other major modelling groups (GSK Vaccines, the Institute for Disease Modeling, and the Swiss Tropical and Public Health Institute) as part of a rigorous harmonisation and model comparison exercise. Our conclusions were presented to the WHO Strategic Advisory Group of Experts (SAGE) and Malaria Policy Advisory Committee (MPAC), and formed one of many lines of evidence considered by the WHO prior to a recommendation decision.
In more recent work we have focussed on the relative impact of RTS,S compared with (and in combination with) other interventions. We continue to work closely with the WHO and the Malaria Vaccines Initiative (MVI) to ensure that this valuable tool in the fight against malaria is deployed in the most efficient way.
Penny, MA, Verity, R, Bever, CA, Sauboin, C, Galactionova, K, Flasche, S, White, MT, Wenger, EA, Van de Velde, N, Pemberton-Ross, P, Griffin, JT, Smith, TA, Eckhoff, PA, Muhib, F, Jit, M, Ghani, AC. (2015). Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. The Lancet, Epub ahead of print. Publisher’s link.
White, MT, Verity, R, Griffin, JT, Asante, KP, Owusu-Agyei, S, Greenwood, B, Drakeley, C, Gesase, S, Lusingu, J, Ansong, D, Adjei, S, Agbenyega, T, Ogutu, B, Otieno, L, Otieno, W, Agnandji, ST, Lell, B, Kremsner, P, Hoffman, I, Martinson, F, Kamthunzu, P, Tinto, H, Valea, I, Sorgho, H, Oneko, M, Otieno, K, Hamel, MJ, Salim, N, Mtoro, A, Abdulla, S, Aide, P, Sacarlal, J, Aponte, JJ, Njuguna, P, Marsh, K, Bejon, P, Riley, EM, Ghani, AC, (2015). Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial, Lancet Infectious Diseases, 15. Publisher’s link.
Winskill, P, Walker, PGT, Griffin, JT, Ghani, AC,(2017),Modelling the cost-effectiveness of introducing the RTS,S malaria vaccine relative to scaling up other malaria interventions in sub-Saharan Africa, BMJ Global Health, 2(1), e000090. Publisher's link.